Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock, Jeremiah A. Aakre, Anna Castillo, et al.
Neurology (2023) Vol. 101, Iss. 19
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

2024 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3708-3821
Open Access | Times Cited: 607
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 559
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Sarah J. Doran, Russell P. Sawyer
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 28
Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
A. Laurell, Ashwin Venkataraman, Tatjana Schmidt, et al.
The British Journal of Psychiatry (2024) Vol. 224, Iss. 6, pp. 198-204
Open Access | Times Cited: 17
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
Eric E. Smith, Natalie A. Phillips, Howard Feldman, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100068-100068
Open Access | Times Cited: 2
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access | Times Cited: 2
New horizons in the diagnosis and management of Alzheimer’s Disease in older adults
Helena Dolphin, Adam H. Dyer, Laura Morrison, et al.
Age and Ageing (2024) Vol. 53, Iss. 2
Open Access | Times Cited: 13
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease
Ruth Dobson, Katherine Patterson, Reshad Malik, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 9, pp. 796-803
Open Access | Times Cited: 9
Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome
Hampus Hillerstrom, Richard A. Fisher, Matthew P. Janicki, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3649-3656
Open Access | Times Cited: 8
Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer's disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
Johannes C. Michaelian, Christopher C. Rowe, Susan Kurrle, et al.
Internal Medicine Journal (2025)
Open Access | Times Cited: 1
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics
Nicolas Villain, Vincent Planche, Matthieu Lilamand, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100094-100094
Open Access | Times Cited: 1
Driving research on successful aging and neuroprotection in Latin America: Insights from the inaugural symposium on brain resilience and healthy longevity
Yakeel T. Quiroz, David Aguillón, Joseph F. Arboleda‐Velásquez, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access | Times Cited: 1
Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias
Arjun V. Masurkar, Karyn Marsh, Brianna Morgan, et al.
Annals of Neurology (2024) Vol. 96, Iss. 4, pp. 633-649
Open Access | Times Cited: 8
Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation
Anna Dittrich, Eric Westman, Sara Shams, et al.
Neurology (2024) Vol. 102, Iss. 9
Open Access | Times Cited: 7
Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives
Sebastian Walsh, Richard L. Merrick, Richard Milne, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6639-6646
Open Access | Times Cited: 7
Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators
Daphne N. Weemering, Anita Beelen, Tessa Kliest, et al.
Neurology (2024) Vol. 103, Iss. 1
Open Access | Times Cited: 6
Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Semira Abdi Beshir, Nadia Hussain, Vineetha Bharathan Menon, et al.
International Journal of Alzheimer s Disease (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 6
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Michael T. Heneka, David Morgan, Frank Jessen
The Lancet (2024) Vol. 404, Iss. 10468, pp. 2198-2208
Closed Access | Times Cited: 6
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
Michael Rosenbloom, Tricia O’Donohue, Domi Zhou-Clark, et al.
CNS Drugs (2024) Vol. 38, Iss. 7, pp. 493-505
Open Access | Times Cited: 5
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
F. Jessen, Milica G. Kramberger, Davide Angioni, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues
Simone Salemme, Antonio Ancidoni, Nicoletta Locuratolo, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 12, pp. 1113-1129
Closed Access | Times Cited: 11
Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort
Elisa Canu, Giulia Rugarli, Federico Coraglia, et al.
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2716-2729
Closed Access | Times Cited: 4
Drugs for Alzheimer’s disease: Where are we coming from? Where are we going?
Davide Angioni, Julien Delrieu, Nicola Coley, et al.
Science Bulletin (2024) Vol. 69, Iss. 10, pp. 1369-1374
Open Access | Times Cited: 4
Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease
Maria Luisa De Paolis, Ilaria Paoletti, Claudio Zaccone, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Digital Clock and Recall: a digital, process-driven evolution of the Mini-Cog
Joyce Gomes‐Osman, Soo Borson, Claudio Toro‐Serey, et al.
Frontiers in Human Neuroscience (2024) Vol. 18
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top